We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Innate Pharma | EU:IPH | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.91% | 2.225 | 2.225 | 2.245 | 2.26 | 2.22 | 2.245 | 29,870 | 14:41:52 |
From May 2023 to May 2024
By Chris Wack
Innate Pharma shares were up 8% to $3.25 after Sanofi said that the U.S. Food and Drug Administration has granted Fast Track Designation for SAR'579/IPH6101 for the treatment of hematological malignancies.
Fast Track Designation is an FDA process designed to facilitate the development, and expedite the review of, medicines to treat serious conditions and fill unmet medical need.
SAR'579 is a trifunctional anti-CD123 cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 08, 2023 10:38 ET (14:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Innate Pharma Chart |
1 Month Innate Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
